Introduction {#sec1-1}
============

Nausea and vomiting are among the most common complaints of patients referred to the emergency department, and kidney stones are the third most commonly reported urinary tract infection after infections and prostate diseases \[[@ref1]\]. One of the most common manifestations of this disease after acute pain is nausea and vomiting \[[@ref2]\].

Currently, Treatments such as venous morphine and NSAIDs) Ketorolac (are currently used for the treatment of renal colic \[[@ref3]\] \[[@ref4]\] \[[@ref5]\]. Although these drugs are widely used in the treatment of renal colic, however, these drugs are applied to treat acute pain. There is little evidence for the treatment of nausea and vomiting in renal colic patients (in particular) referred to the emergency department. Treatment of nausea and vomiting in patients, in addition to facilitating the patient's well-being and better collaboration, prevents complications such as dehydration, hypokalemia, aspiration \[[@ref6]\]. Treatment of nausea and vomiting in patients, in addition to facilitating the patient's well-being and better collaboration, prevents complications such as dehydration, hypokalemia, aspiration \[[@ref7]\]. Although evidence is available on the use of antiemetic drugs in oncology, post-operative nausea and vomiting \[[@ref8]\], and other conditions associated with nausea and vomiting \[[@ref9]\], however, little research has been done to apply these medications for the treatment of nausea and vomiting in patients referred to an emergency such as patients with renal colic \[[@ref6]\]. Although metoclopramide is one of the most widely employed drugs for the improvement of nausea and vomiting in patients \[[@ref6]\]; however, the occurrence of extrapyramidal side effects due to the use of this drug has always been a factor in the cautious use of the drug \[[@ref10]\] \[[@ref11]\].

Nevertheless, the increasing trend of the use of ondansetron in improving nausea and vomiting in emergency rooms is seen in comparison with metoclopramide \[[@ref6]\] \[[@ref10]\] \[[@ref11]\]. Further evidence has focused on the Preventive or therapeutic roles of these drugs in patients undergoing chemotherapy and surgery \[[@ref6]\] \[[@ref7]\] \[[@ref8]\], where there is little evidence for comparing these two drugs in the treatment of patients presenting to the emergency department \[[@ref6]\]. It has recently been reported that the use of serotonin receptor antagonist (Granisetron) can be significantly more effective than metoclopramide in preventing nausea and vomiting in patients undergoing cataract surgery \[[@ref12]\].

To prevent postoperative nausea and vomiting after laparoscopic cholecystectomy surgery, it has been shown that patients receiving ondansetron with dexamethasone before surgery had a lower prevalence of postoperative nausea and vomiting than the dexamethasone group alone \[[@ref13]\]. The importance of improving nausea and vomiting in patients referred to an emergency such as patients with renal colic is well known. The prevention of complications from continuous nausea and vomiting and the lack of evidence for drug therapies in the emergency department, such as metoclopramide and serotonin receptor antagonists (ondansetron), suggest that comparative studies are required about these drugs.

Therefore, the present study was aimed to compare the efficacy of metoclopramide and ondansetron in the improvement of nausea and vomiting in patients referred to the emergency department.

Material and Methods {#sec1-2}
====================

A randomised, double-blind, clinical trial study was conducted among patients referring to the emergency ward of Vali-e-Asr Hospital in Arak, Iran with renal colic and nausea and vomiting. The occurrence of renal colic was determined based on the medical history of the subjects and the clinical manifestations of these patients (type and severity of pain and blood in the urine) (3 and 14). The sampling method was carried out using available samples based on inclusion and exclusion criteria.

The inclusion criteria were considered as follow: 1) patients with renal colic and complained of nausea and vomiting; 2) patients classified as ASA I and II; 3) patients 18 to 80 years; 4) obtaining informed consent from patients.

The exclusion criteria included: 1) hypotension (systolic blood pressure \< 90) and unstable hemodynamics in general; 2) drug addiction; 3) uncontrolled underlying disease (Parkinson's disease, restless leg syndrome, epilepsy, gastrointestinal bleeding, Pheochromocytoma, etc.) \[[@ref2]\]; 4) recent use of central nervous system depressants; 5) recent use of anti-nausea and vomiting drugs (at least the past 8 hours); 6) a previous known allergic reaction to metoclopramide or ondansetron.

Patients willing to participate in the study were evaluated regarding the inclusion and exclusion criteria, and basic information (age and sex) was then obtained. For all patients, 5 mg intravenous morphine was injected with distilled water to a final volume of 10 cc, and patients received Ketorolac ampules for controlling renal colic \[[@ref4]\] \[[@ref5]\]. Then, the patients were randomly divided into 2 groups: group 1 (90 subjects receiving 10 mg intravenous metoclopramide) and group 2 (90 subjects receiving 4 mg intravenous ondansetron). It should be noted that the patients of the two groups were matched regarding age and sex. Patients were evaluated for the response variables at the 0 and 30 minutes after drug injection, that were considered as follow: 1) the severity of nausea; 2) the number of vomiting; 3) vital signs (systolic, diastolic and patient temperature); 4) the need for additional drug therapy after 30 minutes to improve nausea and vomiting; 5) drug side effects. It is worth noting that the patients were matched in two groups according to their age, sex and severity of nausea (5-10 cm based on VAS).

The severity of nausea in the two groups was evaluated before the injection of drugs (0), and 30 minutes after taking the drugs by VAS (Visual Analogue Scale). This criterion consists of a 10 cm ruler extending longitudinally between zero and 10, in which the zero number indicates no pain, and the number 10 indicates an unbearable pain. Patients were asked to mark their pain in this ruler the patient's markup distance from point 0 indicates the patient's pain level \[[@ref15]\].

The frequency of vomiting was also evaluated from patients 30 minutes before injection and up to 30 minutes after medication administration based on patient information and medical history. The vital signs of the patients were measured at 0 and 30 minutes. Drug complications were also documented by the presence of the following variables or other symptoms (based on the diagnosis of an emergency physician) after the injection of drugs based on the patient's history and doctor's visit.

Criteria for metoclopramide included akathisia, dyskinesia, and other extrapyramidal side-effects, dizziness, restlessness, muscle spasm, sweating, etc. The ondansetron criteria were as follows: dizziness, abdominal pain, rash, diarrhoea, etc. It is noteworthy that the task of selecting patients and prescribing drugs for patients was to the emergency medicine specialist. The resident researcher is responsible for reviewing and recording the clinical response variables of patients. In this study, assistant specialist and patients are blind to the type of injectable treatment. For this reason, the drug content in the 10 cc syringes was first prepared by a nurse and administered by the assistant specialist who was blind to the type of treatment.

Because in the treatment of patients referred to the emergency department the first exposure to anaesthetics and vomiting drugs (such as metoclopramide or endonestrone) is used, the placebo group was not considered to be due to the deprivation of these patients. Regarding the treatment of patients referred to the emergency department in the first step with anti-nausea and vomiting drugs (such as metoclopramide or ondansetron), the placebo group was not considered in the study due to the deprivation of these patients from treatment.

Data analysis was performed using SPSS 21 software. To analyse the results, we used mean indexes, standard deviation, standard error, the percentage of frequency. Moreover, the covariance analysis test, Chi-square and Independent T-test or its nonparametric equation or its nonparametric equation were used to compare the mean.

Results {#sec1-3}
=======

In this double-blind clinical trial, 180 patients were enrolled, and 90 patients were randomly assigned to receive metoclopramide and 90 patients to the ondansetron group.

The mean and standard deviation in the metoclopramide group and ondansetron group determined to be 34.56 ± 8.98 and 33.2 ± 8.5, respectively. There was no statistically significant difference between the two groups regarding age (P = 23.88). Mean, and standard deviation of metoclopramide group was calculated as 171.48 ± 6.26 while this level was determined to be 172.77 ± 5.32 for ondansetron group, no statistically significant difference was found between the two groups regarding height (P = 307). As shown in [Table 1](#T1){ref-type="table"}, the mean and standard deviation of pain score at 0, 30, and 60 minutes did not show a significant difference. This suggests that the severity of pain in the ondansetron group was less than the metoclopramide group at these moments.

###### 

Mean and standard deviation of pain score in control and case groups; T indicates the time

                Group            Mean   *Standard Deviation*   P value
  ------------- ---------------- ------ ---------------------- ---------
  T 0           Metoclopramide   97.8   83.0                   0.408
  Ondansetron   07.9             78.0                          
  T 30          Metoclopramide   97.4   46.1                   0.001
  Ondansetron   13.4             90.0                          
  T 60          Metoclopramide   07.3   54.0                   0.001
  Ondansetron   58.2             49.0                          

The mean and standard deviation of systolic blood pressure in 0 minutes were determined in the metoclopramide and ondansetron groups as 136.74 ± 10.15 and 137.03 ± 7.54, respectively, where there was no statistically significant difference between the two groups for systolic blood pressure (P = 0.829).

The mean and standard deviation of systolic blood pressure of 30 minutes in metoclopramide and ondansetron groups were 130.62 ± 7.81 and 128.75 ± 8.22, respectively. There was no significant difference between the two groups regarding systolic blood pressure at 30 min (P = 0.120). The mean and standard deviation of systolic blood pressure during 60 minutes in the metoclopramide group were determined as 124.91 ± 9.05, while these values for the ondansetron group was calculated to be 124.73 ± 6.24. However, there was no significant difference between the two groups regarding systolic blood pressure (P = 0.088).

On the other hand, the mean and standard deviation of diastolic blood pressure *in 0 minutes* was determined in metoclopramide and ondansetron groups as 81.68 ± 6.61 and 81.33 ± 6.78, respectively, which demonstrated no significant difference between the two groups regarding diastolic blood pressure (p = 722).

Furthermore, the mean and standard deviation of diastolic blood pressure were determined in the metoclopramide group during the 30 and 60 minutes as 77.51 ± 7.63 and 73.58 ± 7.44, respectively, while these values in the ondansetron group were 76.22 ± 7.10 and 73.33 ± 6.75 were calculated. According to the P value, there was no significant difference between the two groups regarding diastolic blood pressure in the mentioned minutes (P = 0.243; p = 0. 810).

The mean and standard deviation of heart rate at 0, 30, and 60 minutes after receiving metoclopramide and ondansetron by patients are summarised in [Table 2](#T2){ref-type="table"}. The results of this study revealed that there was a significant difference in heart rate between the two groups receiving the drug 30 and 60 minutes after the intervention, indicating that the heart rate in the metoclopramide group was higher as compared to the ondansetron group (p = 0.001; p = 0.001).

###### 

Mean and heart rate deviation in case and control groups; T shows time

                Group            Mean    *Standard Deviation*   P value
  ------------- ---------------- ------- ---------------------- ---------
  T 0           Metoclopramide   14.96   41.3                   6860\.
  Ondansetron   90.95            59.4                           
  T 30          Metoclopramide   64.82   19.4                   0.001
  Ondansetron   33.79            51.3                           
  T 60          Metoclopramide   31.77   77.5                   0.001
  Ondansetron   78.73            99.2                           

Based on the results presented in [Table 3](#T3){ref-type="table"}, the mean and standard deviation of body temperature in 0, 30 and 60 minutes after intervention were calculated in metoclopramide and ondansetron groups. There was a statistically significant difference between the two groups regarding body temperature after 0 and 30 minutes (p = 0.001; p = 0.002). This finding suggests that body temperature was lower in the metoclopramide group when comparing with the ondansetron group in times above. Nevertheless, the mean and standard deviation of body temperature after 60 minutes in two groups did not exhibit significant difference (p = 1.000).

###### 

Mean and deviation of morphine in both case and control groups

                      Group            Mean   Standard Deviation   P value
  ------------------- ---------------- ------ -------------------- ---------
  Morphine at 0 min   Metoclopramide   96.6   92.0                 0.653
  Ondansetron         91.6             71.0                        
  Morphine at 30min   Metoclopramide   76.0   31.1                 0.484
  Ondansetron         63/0             23/1                        

The mean and standard deviation of the need for morphine at 0 and 30 minutes in both groups were shown in [Table 4](#T4){ref-type="table"}, where no significant difference was observed between the two groups at both times.

###### 

Mean and standard deviation of morphine in both case and control groups; T indicates the time

                 Group            Mean   Standard deviation   P value
  -------------- ---------------- ------ -------------------- ---------
  Morphine T0    Metoclopramide   96.6   92.0                 0.653
                                                              
  Ondansetron    91.6             71.0                        
                                                              
  Morphine T30   Metoclopramide   76.0   31.1                 0.484
                                                              
  Ondansetron    63.0             23.1                        

As indicated in [Table 5](#T5){ref-type="table"}, the mean and standard deviation of nausea in 0, 15, 30, 45, 60 and 120 minutes after intervention in the two groups did not show a significant difference.

###### 

Mean and standard deviation of nausea rate in case and control groups; T indicates the time

  Group                                  Mean   Standard deviation   P value
  --------------------- ---------------- ------ -------------------- ---------
  Vomiting at 0 min     Metoclopramide   02.3   62.0                 1.000
   Ondansetron          03.3             73.0                        
  Vomiting at 15 min    Metoclopramide   51.1   50.0                 0.001
   Ondansetron          35.1             52.0                        
  Vomiting at 30 min    Metoclopramide   65.0   47.0                 0.001
   Ondansetron          36.0             48.0                        
  Vomiting at 45 min    Metoclopramide   38.0   49.0                 0.001
   Ondansetron          04.0             20.0                        
  Vomiting at 60 min    Metoclopramide   12.0   32.0                 0.001
   Ondansetron          08.0             36.0                        
  Vomiting at 120 min   Metoclopramide   07.0   26.0                 0.001
   Ondansetron          02.0             31.0                        

Furthermore, the results of the present study showed that the mean and standard deviation of vomiting in both groups were not statistically significant at 0 minutes, while after intervention, there was a significant difference between the two groups, where vomiting in minutes after intervention (Time: 0, 16, 30, 45, 60, 120) was significantly higher in the metoclopramide group than the ondansetron group.

Discussion {#sec1-4}
==========

Renal colic is one of the most common urological emergencies that is very painful for the patient. The renal colic annually affects 1.2 million people, accounting for about 1% of hospital admissions \[[@ref16]\]. The incidence of kidney stones for men and women is about 12% and 4% throughout life, respectively, which the disease is affected by age, family history, race, place of residence, occupation \[[@ref17]\].

This double-blind clinical trial was conducted to compare the efficacy of Metoclopramide and ondansetron in the treatment of nausea and vomiting in patients with renal colic. The results of our study showed that there was no statistically significant difference between the two groups regarding age, height and weight, where the two groups were matched. There was no statistically significant difference between the mean score of pain in 0 minutes in the intervention and control groups. However, there was a significant difference between the two groups regarding mean pain score in the 30th and 60th minutes, which indicates the severity of pain in the ondansetron group was less than the metoclopramide group.

Moreover, there was no significant difference between systolic and diastolic blood pressure in the two groups at 0, 30 and 60 minutes. Furthermore, no significant difference was found between the two groups in terms of heart rate at 0 minutes; however the mean difference was statistically significant between the two groups in terms of heart rate at 30 and 60 minutes, indicating that the heart rate was lower in the metoclopramide group at 30 and 60 minutes as compared to the ondansetron group.

Based on the data presented here, the mean and standard deviation of body temperature at 0 and 30 minutes exhibited a significant difference between the two groups, indicating that the body temperature in the metoclopramide group was lower than the ondansetron group. The mean and standard deviation of initial morphine and morphine levels of 30th minutes did not reveal any significant difference between the two groups. Also, the mean and standard deviation of nausea in minutes 0, 15, 30, 45, 60 and 120 were not significantly different between the two groups. Mean, and standard deviation of vomiting was not significantly different between the two groups at 0 minutes, while the remaining minutes, 15, 30, 45, 60 and 120, demonstrated a significant difference between the two groups, indicating that the vomiting rate in the metoclopramide group was higher when comparing with ondansetron group.

As other previous study indicated the decreased rate of nausea severity for nausea and vomiting were determined to be similar for 20 mg intravenous metoclopramide, and 4 mg intravenous ondansetron, as well as placebo. However, this was not significant, and the changes were not significant in the two drug groups compared to the placebo group \[[@ref6]\], while, the rate of nausea was similar in both groups in our study, but the vomiting rate in the ondansetron group was lower than the metoclopramide group \[[@ref6]\].

Zahedi study has shown that both metoclopramide and ondansetron have been significantly and prominently effective in preventing nausea and vomiting in these patients during spinal anaesthesia for cesarean section, and their effect on reducing nausea and vomiting is significantly greater compared with placebo group. While our findings revealed that the effect of ondansetron on nausea and vomiting was more than metoclopramide, which our results were not consistent with the findings of the study above \[[@ref18]\]. It has been reported that droperidol was more effective than metoclopramide or prochlorperazine in patients with moderate to severe nausea, but extrapyramidal symptoms could be increased, where metoclopramide and prochlorperazine have had a proportional effect on the improvement of nausea and vomiting of patients referred to the emergency department, as well as we're not seen to be more effective compared to the saline placebo \[[@ref19]\]. Our study on nausea recovery was consistent with the study above. Contrary, the results of vomiting improvement were not similar to the present study.

Another study showed that ondansetron and metoclopramide, plus dexamethasone, did not show a significant effect on postoperative nausea and vomiting after laparoscopic cholecystectomy surgery and was not consistent with our results \[[@ref20]\].

The findings of our study revealed that ondansetron was more effective than metoclopramide in preventing and improving vomiting in patients referred to emergency suffering from renal colic. Therefore, ondansetron can be used with more efficacy and more acceptable side effects to improve nausea and vomiting.
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